Hoth Therapeutics Engages ICON to Expand Clinical Trial for HT-001\n\nAdditional clinical sites in the EU will assess HT-001 for the treatment of skin toxicities associated with EGFRi.\n\nHoth Therapeutics, Inc., a clinical-stage biopharma company, has engaged ICON Clinical Research Ltd. to expand its Phase II clinical trial for cancer patients with skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).\n\nAdditional regulatory approval for the Phase II trial is expected from potentially three EU countries in the upcoming months. The EU approval is part of the company’s international clinical development strategy for HT-001. The trial is currently enrolling patients in multiple sites in the U.S. This Phase 2a dose- ranging study will investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.\n\n\"We are delighted with the addition of clinical sites in the EU and for a strong partnership with ICON. ICON was selected based on their previous clinical trial management experience and their interest in novel therapies,\" said Robb Knie, CEO of Hoth Therapeutics. \"Broadening the clinical presence in the EU serves dual purposes. First, it addresses the near-term objective of completing enrollment of the Phase II trial. Additionally, the initiation of sites in the EU establishes the groundwork for realizing our long-term goal of conducting a global Phase III trial.\"

Hoth Therapeutics Engages ICON to Expand Clinical Trial for HT-001

Hoth Therapeutics, a clinical-stage biopharma company, has partnered with ICON Clinical Research Ltd. to expand its Phase II clinical trial for HT-001, a treatment for skin toxicities associated with EGFRi. The trial will include additional clinical sites in the EU and is part of the company’s international strategy. Regulatory approval from three EU countries is expected, with the trial currently enrolling patients in the U.S. The study aims to evaluate HT-001’s efficacy, safety, and tolerability.